3.82
price down icon4.02%   -0.16
after-market Dopo l'orario di chiusura: 3.89 0.07 +1.83%
loading
Precedente Chiudi:
$3.98
Aprire:
$3.9
Volume 24 ore:
117.15K
Relative Volume:
0.76
Capitalizzazione di mercato:
$41.25M
Reddito:
-
Utile/perdita netta:
$-19.25M
Rapporto P/E:
-2.1461
EPS:
-1.78
Flusso di cassa netto:
$-17.87M
1 W Prestazione:
-1.80%
1M Prestazione:
-15.86%
6M Prestazione:
+9.46%
1 anno Prestazione:
+9.46%
Intervallo 1D:
Value
$3.75
$3.95
Intervallo di 1 settimana:
Value
$3.70
$4.28
Portata 52W:
Value
$2.55
$6.118

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Nome
Lantern Pharma Inc
Name
Telefono
972-277-1136
Name
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Dipendente
24
Name
Cinguettio
@lanternpharma
Name
Prossima data di guadagno
2025-08-08
Name
Ultimi documenti SEC
Name
LTRN's Discussions on Twitter

Confronta LTRN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LTRN
Lantern Pharma Inc
3.82 42.98M 0 -19.25M -17.87M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-10-07 Iniziato H.C. Wainwright Buy

Lantern Pharma Inc Borsa (LTRN) Ultime notizie

pulisher
01:09 AM

How Lantern Pharma Inc. stock reacts to oil pricesWeekly Loss Report & Safe Capital Growth Tips - newser.com

01:09 AM
pulisher
12:33 PM

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - BioSpace

12:33 PM
pulisher
Oct 28, 2025

Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress - Digital Journal

Oct 28, 2025
pulisher
Oct 28, 2025

Will Lantern Pharma Inc. stock recover after recent dropWeekly Risk Report & Growth-Oriented Investment Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Using economic indicators to assess Lantern Pharma Inc. potentialIPO Watch & Target Return Focused Picks - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results for LP-284 - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Lantern Pharma presents LP-284 clinical data at 25th LL&M Congress - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Is Lantern Pharma Inc. stock attractive for income investorsInsider Selling & Weekly Return Optimization Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

What technical signals suggest for Lantern Pharma Inc. stockGDP Growth & Growth Focused Stock Pick Reports - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Is Lantern Pharma Inc. stock a buy before product launchesTrade Volume Summary & Advanced Technical Analysis Signals - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Lantern Pharma Inc. stock trendline breakdown2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Lantern Pharma Inc. stock maintain dividend yieldQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Why Lantern Pharma Inc. stock is favored by pension fundsTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

When is the best time to exit Lantern Pharma Inc.July 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace

Oct 27, 2025
pulisher
Oct 26, 2025

How to interpret RSI for Lantern Pharma Inc. stock2025 Macro Impact & AI Forecasted Stock Moves - newser.com

Oct 26, 2025

Lantern Pharma Inc Azioni (LTRN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Lantern Pharma Inc Azioni (LTRN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Kreis Leslie W.
10% Owner
Jun 13 '25
Sale
3.09
40,000
123,600
49,957
Fletcher Aaron G.L.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Fletcher Aaron G.L.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Fletcher Aaron G.L.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Kreis Leslie W.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Kreis Leslie W.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Kreis Leslie W.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Fletcher Aaron G.L.
10% Owner
May 27 '25
Sale
3.05
21,037
64,163
56,467
Fletcher Aaron G.L.
10% Owner
May 29 '25
Sale
3.03
20,200
61,206
54,792
Fletcher Aaron G.L.
10% Owner
May 28 '25
Sale
2.87
15,000
43,050
55,753
$36.67
price up icon 0.71%
$90.18
price down icon 1.60%
$28.95
price down icon 0.62%
$103.35
price down icon 1.60%
biotechnology ONC
$314.85
price down icon 0.63%
$166.95
price up icon 1.00%
Capitalizzazione:     |  Volume (24 ore):